An observational study in Mild Cognitive Impairment (MCI) and Depression and Anxiety Symptoms, sponsored by University Medical Centre Maribor. Not yet recruiting at 1 site in Slovenia. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University Medical Centre Maribor · Observational
Among 12 studies in Cognitive Dysfunction with a site in Slovenia — 1 open to participants now, 2 under way, none of them phase 3. Cognitive Dysfunction · Slovenia.
Among the 12 studies in Cognitive Dysfunction with a site in Slovenia, this one is one of 2 that started in 2026, is one of 5 observational ones, and was the 12th registered.
3,872 studies on the registry are indexed under Cognitive Dysfunction; 1,119 are open to participants now.
Browse Cognitive Dysfunction studies →1 of the 12 studies in Cognitive Dysfunction with a site in Slovenia is open now.
A study can be open while its sites in Slovenia have not opened yet or have stopped. Only those recruiting at a site in Slovenia →
Of the 750 Cognitive Dysfunction studies recruiting now, 362 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 259 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 150 across 997 observational studies indexed under Cognitive Dysfunction.
Median enrollment 63 across the 7 interventional studies, 60 across the 5 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 12 have an industry lead sponsor. The 5 most frequent:
University Medical Centre Maribor is the lead sponsor of 37 studies on the registry; 9 are open to participants now.
University Medical Centre Maribor has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
1 of the studies in Cognitive Dysfunction with a site in Slovenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07931586University Medical Centre MariborMild Cognitive Impairment in Older Adults With and Without Depressive Symptom | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Cognitive Dysfunction with a site in Slovenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will compare adults aged 65 years or older who have mild cognitive impairment, with and without depressive symptoms. The researchers plan to participants at University Medical Centre Maribor, with two equally sized groups. They will compare outcomes in several different cognitive domains (visuospatial abilities, emotional modulation, social cognition) and in DNA methylation of relevant regions (for BDNF, COMT, and SLC6A4 gene promoters).
This cross-sectional observational study will examine cognitive and epigenetic differences between older adults with mild cognitive impairment who have depressive symptoms and those who do not. Potential participants will be identified through the outpatient psychogeriatric, psychiatric, and neurology clinics and the inpatient geriatric psychiatry units at University Medical Centre Maribor. Participants will be aged 65 years or older, have cognitive screening results consistent with mild cognitive impairment, and provide written informed consent. The planned sample will include two equally sized groups of participants.
Participants will be classified according to the presence or absence of depressive symptoms at the initial assessment. Depressive symptoms will be reassessed early in the study to confirm group classification. Participants will receive the same standard of diagnostic assessment and treatment as patients who do not take part in the study.
The study will compare performance on tasks assessing visuospatial abilities, emotional modulation abilities and social cognition. The investigators hypothesize that participants with depressive symptoms will perform better on the visuospatial task and less well on the emotional capture and social cognition tasks than participants without depressive symptoms. Blood samples will be collected to compare DNA methylation in the promoter regions of BDNF, COMT, and SLC6A4 between the two groups.
The study population will consist of adults aged 65 years or older with cognitive screening results consistent with mild cognitive impairment. Potential participants will be identified at University Medical Centre Maribor through the outpatient psychogeriatric, psychiatric, and neurology clinics and the inpatient geriatric psychiatry units. The planned sample includes equal numbers of participants with depressive symptoms without depressive symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 65 years or older with mild cognitive impairment and depressive symptoms, as determined by the study's depression assessment.
Adults aged 65 years or older with mild cognitive impairment without depressive symptoms, as determined by the study's depression assessment.
Visuospatial Task Performance
Visuospatial performance will be measured using computer guided cognitive task (n-back). Values will be compared between participants with mild cognitive impairment with and without depressive symptoms.
Time frame: At the baseline study visit.
Emotional Capture Task Performance
Emotional capture will be assessed using the computer guided Emotional Capture Task. Values will be compared between participants with mild cognitive impairment with and without depressive symptoms.
Time frame: At the baseline study visit.
Social Cognition Performance on the Faux Pas Test
Social cognition will be assessed using the Faux Pas Test. Scores will be compared between participants with mild cognitive impairment with and without depressive symptoms.
Time frame: At the baseline study visit.
Regional DNA Methylation (BDNF, COMT and SLC6A4 promoter gene regions)
DNA methylation will be measured in target regions using DNA obtained from blood samples. Results will be compared between participants with mild cognitive impairment with and without depressive symptoms.
Time frame: At the baseline study visit.
Plan to share: Undecided — A decision has not yet been made about whether de-identified individual participant data from this study will be shared with other researchers.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Centre Maribor